Magnetic Resonance Spectroscopy in Clinical Oncology

@article{Golder2004MagneticRS,
  title={Magnetic Resonance Spectroscopy in Clinical Oncology},
  author={Werner A. Golder},
  journal={Oncology Research and Treatment},
  year={2004},
  volume={27},
  pages={304 - 309}
}
  • W. Golder
  • Published 1 June 2004
  • Medicine
  • Oncology Research and Treatment
The combination of magnetic resonance spectroscopy (MRS) and imaging (MRI) has led to mapping metabolites from normal and neoplastic tissue within the time limits of a routine study. MRSI (magnetic resonance spectroscopy imaging) detects metabolites that contain protons, phosphorus, fluorine, or other nuclei. The uniqueness of the information available in vivo and in a non-invasive manner encouraged radiologists and oncologists to apply MRSI in research and clinical practice. Both 1H- and 31P… 

Tables from this paper

In vivo magnetic resonance spectroscopy in cancer.

Tissue choline has proven to be a tumor biomarker that is significantly affected by anticancer therapies and is focused on in this review on the latter applications of in vivo MRS.

Feasibility of In vivo Proton Magnetic Resonance Spectroscopy for Lung Cancer

In vivo proton MRS method using a single-voxel respiration-triggered point-resolved spectroscopic sequence is feasible in obtaining the MR spectra of lung cancer because these spectra were analyzable and high success rate was shown in this study although there was the limitation of small patient group.

Metabolic brain imaging by magnetic resonance

The methods for obtaining metabolic measurements in vivo by MRS that can be combined with any of these MR methods are discussed, including single voxel MRS, which is a novel adaption of the first method.

Metabolic profiling of human brain metastases using in vivo proton MR spectroscopy at 3T

MRS determined metabolic profiles analysed by PCA and PLS might give valuable clinical information when planning and evaluating the treatment of brain metastases, and also when deciding to terminate further therapies.

Clinical 1h magnetic resonance spectroscopy of brain metastases at 1.5T and 3T

SNR and spectral resolution were improved at higher magnetic field strength, especially with TE 144 ms, including spectra from patients with heterogeneous brain tumors, however, differences in the defined effective VOI, particularly at short echo time, reduced the expected effect of increased magnetic fieldstrength on the measured SNR.

Imaging of brain tumors: MR spectroscopy and metabolic imaging.

Evaluating pH in the Extracellular Tumor Microenvironment Using CEST MRI and Other Imaging Methods.

A comprehensive overview of methods for measuring tumor pHe is provided, including recently developed methods that use chemical exchange saturation transfer MRI that combines some advantages of MR spectroscopy and imaging.

Investigation of compressed-sensing for acceleration of magnetic resonance spectroscopic imaging

Results suggest that CS-MRSI can reduce scan duration by up to a factor of 5 whilst simultaneously eliminating ringing artefacts and increasing spatial resolution compared with conventionally filtered MRSI, suggesting that CS could greatly increase the clinical utility of MRSi.

References

SHOWING 1-10 OF 46 REFERENCES

In Vivo Proton (H1) Magnetic Resonance Spectroscopy for Cervical Carcinoma

H1 MRS of the cervix using a noninvasive pelvic coil consistently demonstrates reproducible spectral differences between normal and neoplastic cervical tissue in vivo, however, signal is still poor for minimal disease recurrence.

The potential of proton magnetic resonance spectroscopy (1H-MRS) in the diagnosis and management of patients with brain tumors

Proton (1H) magnetic resonance spectroscopy is a noninvasive method that can monitor the metabolic changes in most brain diseases and has the potential to guide biopsies, to define radiotherapy targets, and to monitor patients after treatment.

Characterization of intracranial mass lesions with in vivo proton MR spectroscopy.

In vivo proton MR spectroscopy, helps in tissue characterization of intracranial mass lesions and is a reliable technique for grading of gliomas when N-acetyl-aspartate/choline and choline/creatine ratios and presence of lipids are used in combination.

Developments in nuclear magnetic resonance imaging and spectroscopy: application to radiation oncology.

A brief review of magnetic resonance techniques for imaging of tissue physiological function is provided and possible applications in the realm of radiation oncology are addressed.

Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors.

  • K. WarrenJ. Frank F. Balis
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
The maximum tumor Cho:NAA ratio seems to be predictive of outcome in children with recurrent primary brain tumors and should be evaluated as a prognostic indicator in newly diagnosed childhood brain tumors.

Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy.

Parameters from single-voxel proton MR spectroscopy provide a probability measure for differentiating neoplastic from radiation-induced, nonneoplastic lesions after stereotactic radiotherapy of brain tumors.

MR spectroscopy of musculoskeletal soft-tissue tumors.

  • W. Negendank
  • Medicine
    Magnetic resonance imaging clinics of North America
  • 1995
1H-decoupling and NOE-enhancement, implemented in conjunction with dual-tuned surface coils and accurate localization of 31P MR spectra to regions of interest in three dimensions using CSI, have enabled us to overcome the major technical limitations, broaden the scope of31P MRS investigations, and obtain more information about the in vivo metabolic characteristics of soft-tissue sarcomas than has heretofore been available.

MR spectroscopy of musculoskeletal soft-tissue tumors.

1H-decoupling and NOE-enhancement, implemented in conjunction with dual-tuned surface coils and accurate localization of 31P MR spectra to regions of interest in three dimensions using CSI, have enabled us to overcome the major technical limitations, broaden the scope of31P MRS investigations, and obtain more information about the in vivo metabolic characteristics of soft-tissue sarcomas than has heretofore been available.